The role of the endocannabinoid system in alzheimer's disease: Facts and hypotheses

Current Pharmaceutical Design

Volumn 14, Issue 23, 2008, Pages 2299-2305

  Bisogno, Tiziana ^a   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

Author keywords

Alzheimer's Disease; Anti oxidant; Drugs; Endocannabinoid System; Hypotheses; Neuroinflammatory disorders; Non psychotropic cannabidiol; Parkinson's disease

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AMYLOID BETA PROTEIN; ANANDAMIDE; AVE 1625; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CP 5940; DRONABINOL; ENDOCANNABINOID; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; RIMONABANT; UNCLASSIFIED DRUG; WIN 55 212 2;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL ACTIVATION; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG SELECTIVITY; GLIOSIS; HUMAN; MEMORY CONSOLIDATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID; TAU PROTEINS;

EID: 52949112654     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785740027     Document Type: Review

References (52)

1. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20: 154-9.
2. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998; 21: 479-505.
3. Caricasole A, Copani A, Caruso A, Cavaci F, Iacovelli L, Sortino MA, et al. The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci 2003; 24: 233-8.
4. Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, et al. H2O2 and 4-hydroxynonerial mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 2003; 180: 144-55.
5. Hol EM, van Leeuwen FW, Fischer DF. The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B + 1. Trends Mol Med 2005; 11: 488-95.
6. Song S, Jung YK. Alzheimer's disease meets the ubiquitin-proteasome system. Trends Mol Med 2004; 10: 565-70.
7. Moreira PI, Siedlak SL, Aliev G, Zhu X, Cash AD, Smith MA. et al. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 2005; 112: 921-32.
8. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid. Redox Signal 2000; 2, 413-20.
9. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 741-9.
10. Mattson MP. Will calorie restriction and folate protect against AD and PD? Neurology 2003; 60: 690-5.
11. Jellinger KA. Alzheimer 100-highlights in the history of Alzheimer research. J Neural Transm 2006; 113: 1603-23.
12. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006; 113: 1625-44.
13. Roberson ED, Mucke L. 100 years land counting: prospects for defeating Alzheimer's disease. Science 2006; 314: 781-4.
14. Arbel M, Solomon B. Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside. Trends Immunol 2007; 28: 511-3.
15. Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci 2007; 28: 536-43.
16. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008; 22: 1-14.
17. Bisogno T, Di Marzo V. Short- and long-term plasticity of the endocarmabinoid system in neuropsychiatric and neurological disorders. Pharmacol Res 2007; 56: 428-42.
18. Milton NG. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett 2002; 332: 127-30.
19. 2) suppresses microglial activation. J Neuroinflammation 2005; 2: 29-41.
20. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-13.
21. 1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett 2006; 404: 342-6.
22. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, et al. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther 2007; 322: 1144-52.
23. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
24. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 2005; 168: 445-77.
25. 1 receptor blockade. Eur J Pharmacol 2003; 477: 219-25.
26. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels, Cell Mol Life Sci 2006; 63: 1410-24.
27. 2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 2008; 153: 299-308.
28. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-55.
29. Pardon MC, Sarmad S, Rattray I, Bates TE, Scullion GA, Marsden CA, et al. Repeated novel cage exposure-induced improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM mice is unrelated to changes in brain endocannabinoids levels. Neurobiol Aging 2007; in press.
30. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-15.
31. Frankland PW, Bontempi B, Talton LE, Kaczmarck L, Silva AJ. The involvement of the anterior cingulate cortex in remote contextual fear memory. Science 204; 304: 881-83.
32. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268-73.
33. 2 and receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153:199-215.
34. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004; 89: 134-41.
35. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38-MAP kinase and NF-kappaB involvement. Neurosci Lett 2006; 399: 91-5.
36. Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med 2006; 84: 253-8.
37. Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007; 151: 1272-9.
38. Velez-Pardo C, Del Rio MJ. Avoidance of Abeta[(25-35)]/(H(2)O(2)) -induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53. Med Chem 2006; 2: 471-9.
39. Eubanks LM, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ, Dickerson TJ, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006; 3: 773-7.
40. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003; 23: 11136-41.
41. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains.Neuroscience 1994; 63: 637-52.
42. Cowburn RF, O'Neill C, Bonkale WL, Ohm TG, Fastbom J. Receptor-G-protein signalling in Alzheimer's disease. Biochem Soc Symp 2001; 67: 163-75.
43. Wisniewski HM, Wrzolek M. Pathogenesis of amyloid formation in Alzheimer's disease, Down's syndrome and scrapie. Ciba Found Symp 1988, 135: 224-38.
44. Barcikowska M, Silverman W, Zigman W, Kozlowski PB, Kujawa M, Rudelli R, et al. Alzheimer-type neuropathalogy and clinical symptoms of dementia in mentally retarded people without Down syndrome. Am J Ment Retard 1989; 93: 551-7.
45. Núñez E, Benito C, Tolón RM, Hillard CJ, Griffin WS, Romero J. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 2008; 151: 104-10.
46. Volicer L, Stelly M, Morris J, McLaughhn J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 913-9.
47. Pazos MR, Núñez E, Benito C, Tolón RM, Romero J. Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life Sci 2004; 75:1907-15.
48. Campbell VA, Gowran A. Alzheimer's disease: taking the edge off with cannabinoids? Br J Pharmacol 2007; 152: 655-62.
49. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008; 20: 1-9.
50. Musial A, Bajda M, Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem 2007; 14(25): 2654-79.
51. Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds. Prog Drug Res 2008; 65: 47-118.
52. Sadowski M, Wisniewski T. Disease modifying approaches for Alzheimer's pathology. Curr Pharm Des 2007; 13(19): 1943-54.